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A B S T R A C T
There are no data obtained in biopsy material on the prevalence of human papillomavirus (HPV) and HPV genotypes
in Croatian women with cervical carcinoma and precursor lesions. Therefore, the prevalence of HPV and HPV genotypes
was investigated in archival material of cervical carcinoma and precursor lesions kept at Department of Pathology,
School of Medicine, University of Rijeka. DNA was isolated from formalin fixed, paraffin embedded tissue, histologi-
cally classified as cervical intraepithelial neoplasia (CIN) III (n=43), squamous cell carcinoma (SCC) (n=54) and ade-
nocarcinoma (ADC) (n=40). HPV testing was performed by polimerase chain reaction (PCR) using generic and genotype
specific primers. The prevalence of HPV DNA was 93.02%, 92.59%, and 92.5% in CIN III, SCC and ADC, respectively. In
CIN III and SCC, HPV-16 was the most common high-risk genotype, identified in 65% and 52%, followed by HPV-18 in
22.5% and 28% of cases, respectively. HPV-18 showed a statistically significant prevalence in ADC (67.6%) as compared
with SCC (2=9.924; p 0.01). Study results revealed a high prevalence of HPV-DNA in examined cervical lesions (>90%).
HPV-16 predominated in SCC and HPV-18 in ADC. Single infection was more frequently present than multiple infec-
tions in all three histological groups.
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Introduction
Approximately 510,000 cases of cervical cancer are re-
ported each year, with nearly 80% in developing coun-
tries1,2. Epidemiological studies indicate a strong associa-
tion of high-risk human papillomavirus (HPV) genotypes
with cervical carcinoma and malignant transformation
of cervical epithelial cells3. Recent studies have shown
that more than 90% of cervical cancers contain HPV
DNA, and some are even suggesting that there is no cer-
vical cancer without HPV infection4–7. More than 50
HPV genotypes are known to infect female genital tract,
and a subset of ~12 of these are known to have a strong
oncogenic potential8. Therefore, HPV genotypes have
been classified according to their association with cervi-
cal cancer and precursor lesions into high-risk (onco-
genic) and low-risk HPV genotypes9. The most prevalent
high-risk HPV genotypes worldwide, which infect uterine
cervix, are HPV-16 (~53%), followed by HPV-18 (~15%),
HPV-45 (~9%), HPV-31 (~6%) and HPV-33 (~3%)10.
According to the Croatian National Cancer Regis-
try11, the incidence of cervical cancer in 2002 was 15.9
new cases per 100,000 women, yet there are only a few
reports describing HPV genotype distribution in abnor-
mal cervical PAP smears in Croatia12–14. There are no
data obtained in biopsy material on the prevalence of
HPV and HPV genotypes in Croatian women with cervi-
cal carcinoma and precursor lesions. Therefore we em-
barked upon this retrospective analysis to assess the dis-
tribution of HPV genotypes in the archival material kept
at Department of Pathology, School of Medicine, Univer-
sity of Rijeka. Archival (cervical intraepithelial neopla-
sia) CIN III and cervical carcinomas were analyzed by
polymerase chain reaction (PCR) for the presence of
HPV DNA and distribution of HPV genotypes.
Materials and Methods
A total of 137 formalin fixed, paraffin embedded sam-
ples were chosen on the basis of availability of tissue in
the pathology archive. There were 43 CIN III, 54 squa-
mous cell carcinoma (SCC) and 40 cervical adenocar-
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cinoma (ADC) (including 15 adenocarcinoma in situ (AIS)
specimens obtained from patients treated at Department
of Gynecology and Obstetrics, Rijeka University Hospital
Center, during the 1995–2005 period. The samples were
histopathologically examined by an expert pathologist at
Department of Pathology, School of Medicine, University
of Rijeka. The mean age of patients with CIN III diagno-
sis was 31.5, range 24–50 years. In SCC group there were
21 patients with microinvasive carcinoma (MICA). The
mean age of patients with MICA and invasive SCC was
40 (range 30–48) and 46 (range 34–67) years, respec-
tively. The mean age of patients with AIS and invasive
ADC was 39 (range 26–53) and 45 (range 43–67) years,
respectively.
DNA extraction
Total DNA was isolated from formalin fixed, paraffin
embedded samples. Great care was taken on sample sec-
tioning to avoid any contamination between the samples.
Depending on the amount of biopsy material embedded
in paraffin, 4–10 sections (5 mm thick) were placed in a
microcentrifuge tube. The sections were deparaffinized
by adding 1 mL of xylene and heating at 55 oC for 30 min-
utes, followed by centrifugation and subsequent removal
of the supernatant. Upon dewaxing with three washes of
xylene, 1 mL of 100% ethanol was added to remove resid-
ual xylene. The tissues were dried at 37 oC for 30 minutes
and DNA was isolated using NucleoSpin,Tissue kit (Ma-
charey-Nagel, Duren, Germany) according to the manu-
facturer’s instructions.
PCR analysis
To assess the quality of extracted DNA, b-globin PCRs
were performed using four primer combinations span-
ning 110, 250, 345 and 408 bp (Takara Biomedicals, Ja-
pan). Primers targeting highly conserved regions within
the L1 and E6/E7 open reading frame (ORF) were used
to detect HPV DNA. These included the GP5+/GP6+15
and SPF 10 primers (INNO-LiPA Genotyping, Inno-
genetics N.V., Ghent, Belgium) of the L1 ORF and prim-
ers from Human Papillomavirus Typing Set (Takara
Biomedicals, Japan), which amplify sequences within E6
and E7 ORF. The HPV types in positive samples were
further characterized by using hybridization assay for
identification of HPV genotypes (INNO-LiPA Genotyp-
ing, Innogenetics N.V., Ghent, Belgium) and type specific
PCR amplifying sequences of HPV-16, 18, and 33 within
E6 and E7 ORF (Human Papillomavirus Detection Set,
Takara Biomedicals, Japan).
Statistical analysis
HPV prevalence was expressed as percentage of all
cases tested for HPV in different histological groups (ac-
counted only once). When determining the prevalence of
high- and low-risk HPV genotypes, women were counted
more than once if they harbored multiple infections with
a mixture of both. The prevalence of individual HPV ge-
notypes was determined as they appeared as either single
or multiple infections. Multiple high-risk HPV infection
was defined as two or more high-risk HPV genotypes
with or without additional low-risk HPV genotypes. The
c2 test was used to assess statistical significance of differ-
ences in the prevalence and distribution of HPV geno-
types, and to examine the relationship between multiple
and single HPV infection with different histological
types of cervical cancer. Statistical significance was es-
tablished at the p<0.05 level.
Results
Of 137 study specimens, 127 (91.97%) were positive
for HPV DNA. HPV prevalence according to histological
groups is presented in Table 1 and overall high-risk HPV
prevalence in Table 2. The prevalence of HPV infection
in CIN III, SCC and ADC was 93.02% (40/43), 92.59%
(50/54) and 92.5% (37/40), respectively. In total, 10 differ-
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TABLE 1
HPV DISTRIBUTION ACCORDING TO HISTOLOGICAL GROUPS
Histological group
HPV CIN III SCC ADC
HPV neg. 3 (6.9) 4 (7.4) 3 (7.5)
6/11 – – 1 (2.5)
16 17 (39.5) 22 (40.7) 3 (7.5)
18 3 (6.9) 6 (11.1) 20 (50)
31 2 (4.6) 3 (5.5) 1 (2.5)
33 – – 1 (2.5)
45 – 1 (1.8) –
52 – 1 (1.8) –
6/11+16 4 (9.3) – –
16+18 4 (9.3) 2 (3.7) 1 (2.5)
16+31 – – 1 (2.5)
18+31 – 3 (5.5) –
18+33 2 (4.6) – –
31+33 – 4 (7.4) –
31+52 – 1 (1.8) –
31+70 1 (2.3) – –
45+68 1 (2.3) – –
6/11+16+18 – 2 (3.7) 4 (10)
6/11+18+31 – 1 (1.8) –
16+31+33 – – 1 (2.5)
16+31+52 1 (2.3) – –
31+52+74 – 1 (1.8) –
x 5 (11.6) 3 (5.5) 4 (10)
Total 43 54 40
137
HPV pos. (%) 93.02 92.59 92.5
Values are expressed as number of samples and percentage in
parentheses, CIN – cervical intraepithelial neoplasia, SCC – squ-
amous cell carcinoma, ADC –adenocarcinoma, HPV neg. – all
samples without positive HPV DNA test result, HPV pos. – all
samples with positive HPV DNA test result.
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ent oncogenic HPV genotypes were identified: 9 in CIN
III, 8 in SCC and 5 in ADC. High-risk HPV genotypes
that were most prevalent in all three groups accounted
for 87.5% (35/40) of all HPV positive cases of CIN III,
90.0% (47/50) of SCC and 86.4% (32/37) of ADC. Low-risk
HPVs were detected as part of mixed low/high-risk HPV
infections, except for one ADC case. A great diversity of
high-risk HPV genotypes was detected in the group of
squamous cell lesions, whereas only 4 different HPV ge-
notypes and HPV-X were identified in the ADC group
(Table 1). Overall, HPV-16 was the predominant geno-
type detected in 26/40 (65%) and 26/50 (52.0%) CIN III
and SCC HPV positive cases, respectively. The ADC
group showed a predominance of HPV-18 genotype, re-
corded in 25/37 (67.5%) of all HPV ADC positive cases
(Table 2). The observed predominance of HPV-16 in CIN
III (c2=13.923, p<0.001) and SCC (c2=5.717, p<0.025),
as well as HPV-18 in ADC (c2=11.428, p<0.001) was sta-
tistically significant (Table 3).
In CIN III group, 77.5% (31/40) of the samples were
positive for a single high-risk HPV genotype and 22.5%
(9/40) for multiple high-risk HPV genotypes (Figure 1).
The overall prevalence of high-risk HPV genotypes found
in CIN III in descending order was as follows: HPV-16
(65%), HPV-18 (22.5%), HPV-X (12.5%), HPV-31 (10%),
HPV-33 (4.6%), followed by HPV-45, HPV-52, HPV-68
and HPV-70 (Table 2). Single infection was present in
72% and multiple infections in 28% of SCC cases (Figure
1). Considering overall prevalence of high-risk HPV ge-
notypes in the SCC samples, the predominant genotypes
were HPV-16 (52%), HPV-18 (28%), HPV-31 (26%) and
HPV-33 (8%), followed by HPV-52, HPV-X, HPV-45 and
HPV-74. In the ADC group, 81% (29/36) of the samples
were positive for a single high-risk and 19% (7/36) for
multiple high-risk HPV genotypes (Figure 1). HPV-18 as
the predominant high-risk HPV genotype (67.6%) in the
ADC group was followed by HPV-16 (27%), HPV-X (10.8%),
HPV-31 (8.1%) and HPV-33 (5.4%) (Table 2). The differ-
ence in the predominant HPV-16 genotype distribution
in CIN III and SCC versus HPV-18 in ADC (c2=16.121,
p<0.001) was statistically significant, and so was the dif-
ference yielded by comparison between SCC and ADC
(c2=9.924, p<0.01) samples.
Multiple high-risk HPV infections were found in all
three groups without a statistically significant associa-
tion with the histological diagnosis (Figure 1, Table 1).
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TABLE 2





Overall distribution of HPV types
6/11 16 18 31 33 45 52 68 70 74 x
CIN III (43) 40 4 (10) 26 (65) 9 (22.5) 4 (10) 2 (5) 1 (2.5) 1 (2.5) 1 (2.5) 1 (2.5) 0 (0) 5 (12.5)
SCC (54) 50 3 (6) 26 (52) 14 (28) 13 (26) 4 (8) 1 (2) 3 (6) 0 (0) 0 (0) 1 (2) 3 (6)
ADC (40) 37 5 (13.5) 10 (27) 25 (67.6) 3 (8.1) 2 (5.4) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 4 (10.8)
Total (137) 127 12 (9) 62 (49) 48(38) 20 (16) 8 (6) 2 (2) 4 (3) 1 (1) 1 (1) 1 (1) 12 (9)
Because of the existence of multiple HPV infections, women were counted more than once where appropriate, values are number of
samples and percentage in parentheses. CIN – cervical intraepithelial neoplasia, SCC – squamous cell carcinoma, ADC –adenocar-
cinoma, HPV pos. – all samples with positive HPV DNA test result.
TABLE 3
DISTRIBUTION DIFFERENCE OF HIGH-RISK HPV GENOTYPES
16 AND 18 IN CERVICAL CANCER AND CIN III.






















ADC 40 36 3 10 25 11.428 0.001
CIN – cervical intraepithelial neoplasia, SCC – squamous cell car-
cinoma, ADC – adenocarcinoma
Fig. 1. Prevalence of single and multiple high-risk HPV infections
associated with histological groups of cervical carcinoma. HR-
-HPV – high-risk HPV, CIN – cervical intraepithelial neoplasia,
SCC – squamous cell carcinoma, ADC – adenocarcinoma.
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Discussion
Epidemiological and molecular biology studies have
shown that infection with high-risk HPV is the most im-
portant etiologic agent in the pathogenesis of cervical
SCC 10,16. However, the pathogenic role of HPV in cervi-
cal adenocarcinoma remains unclear17–19. Cross-sectional
studies indicate that HPV infection is most frequently
found among sexually active young women and that its
prevalence decreases with age. In most studies HPV-16
was found to be the most prevalent HPV genotype in cy-
tologically normal women, women with CIN, and women
with cervical cancer7,16. Yet, recent studies have shown
the distribution of HPV genotypes detected in cervical
cancer to vary depending on the histological type of the
cancer. Whereas HPV-16 is the most frequent genotype
in SCC, HPV-18 is a predominant genotype in ADC and
AIS20–23. Some studies indicate that both HPV-16 and
HPV-18 play a prominent role in the development of
ADC of the cervix18,19. The overall frequency of HPV
DNA associated with cervical SCC has been reported to
be 91%–100% 7,10; yet, the HPV DNA detected in adeno-
carcinomas varies significantly from 32% to 100%, de-
pending on the detection method used 18. The overall
prevalence of HPV DNA detected in our study in all three
histological groups was high (>90%). We found that
HPV-16 was the most prevalent genotype in CIN III and
SCC, whereas HPV-18 was most frequent in ADC. Our
results are consistent with previous reports, which also
indicate a high occurrence of HPV-16 in CIN III and
SCC22,24. We demonstrated HPV-18 to be the most com-
mon genotype in ADC, which is consistent with several
studies conducted in Europe20,23,25. In our study, the HPV
genotypes detected in ADC were HPV-18, HPV-16, HPV-X,
HPV-31 and HPV-33. The only difference between our
study and the meta-analysis reported by Clifford et al.23
was that we did not detect HPV-45 genotype in ADC,
which could have been due to some specificity of the HPV
genotypes found in this area or a smaller sample size.
The difference in the prevalence of high-risk HPV-16 and
HPV-18 genotypes recorded in SCC and ADC was statis-
tically significant. In most cancer registries, about 75%
of all cervical cancer cases are reported as SCC, whereas
ADC and adenosquamous cell carcinoma account for
10%–15% of cervical cancer cases, with increasing inci-
dence rates during the last decade, particularly in youn-
ger women26. The influence of multiple HPV infection on
the development of cervical carcinoma is still controver-
sial. It has been shown that multiple high-risk HPV in-
fections were less frequent in high grade than in low
grade cervical neoplasia27. Multiple infections were sig-
nificantly less common in ADC, which suggests that the
ultimately invasive growth of glandular epithelial cells is
triggered by the action of a single HPV genotype rather
than by the potentially synergistic action of multiple
HPVs18,28. Our study revealed a single high-risk HPV ge-
notype to be more frequent in CIN III, SCC and ADC
samples.
Taking into account oncogenic potential of HPV-16
and HPV-18, these data deserve special attention in fur-
ther development of screening programs for cervical can-
cer in Croatia, as well as future vaccination programs, to
lessen the burden of this neoplasm.
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PREVALENCIJA GENOTIPOVA HUMANOG PAPILOMA VIRUSA U KARCINOMU
CERVIKSA I PREKURSORSKIM LEZIJAMA
S A @ E T A K
Ispitali smo prevalenciju humanog papilomavirusa (HPV) i distribuciju HPV genotipova u arhivskom materijalu
karcinoma cerviksa i prekanceroznih lezija, prikupljenom u periodu 1995–2005 godina u Zavodu za patologiju, Me-
dicinskog fakulteta Sveu~ili{ta u Rijeci. Iz tkiva uklopljenog u parafin, histolo{ki klasificiranog kao cervikalna intra-
epitelna neoplazija (CIN) III (n=43), plo~asti karcinom cerviksa (SCC) (n=54) i adenokarcinoma cerviksa (ADC) (n=
40) izolirana je DNA, a HPV analiza je izvr{ena pomo}u polimeraza lan~ane reakcije (PCR) koriste}i generi~ke i genotip
specifi~ne PCR primere. Prevalencija HPV-DNA utvr|ena je u 93.02% slu~ajeva CIN-a III, 92.59% SCC-a i 92.5% ADC-a.
Od visoko rizi~nih genotipova HPV-16 je bio naj~e{}i u 65% CIN-ova III i 52% SCC-a, dok je HPV-18 utvr|en u 22.5%
CIN-ova III i 28% SCC-a. Prona|ena je statisti~ki zna~ajna prevalencija HPV-18 genotipa u ADC-u, 67.6%, u usporedbi
sa 28% u SCC-u, (c2=9.924; p	 0.01). U manje od 15 % slu~ajeva utvr|ene su mije{ane infekcije s HPV genotipovima 31,
33, 45, 52, 68, 70 i neutvr|enim genotipom X. U sva tri histolo{ka tipa infekcija s jednim HPV-genotipom bila je do-
minantna u odnosu na mije{anu infekciju.
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